Nektar Therapeutics (NKTR) Stock: Buy, Sell, or Hold?
NKTR - Nektar Therapeutics
$69.76
-0.89 (-1.26%)
▼
5d:
-8.66%
30d:
-8.25%
90d:
+17.82%
HOLD
MODERATE Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 4, 2026 at $74.19 · last confirmed Sep 11, 2026
Strength: 4.8/10
Get Alerted When NKTR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: NKTR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: NKTR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: NKTR is currently trading at $69.76, which is considered extended relative to its 30-day fair value range of $72.21 to $75.61.
Technical Outlook: Technically, NKTR is in a strong uptrend. The price is currently testing key support at $68.35. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $144.40 (+107.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NKTR is in a strong uptrend. The price is currently testing key support at $68.35. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $144.40 (+107.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$72.21 -
$75.61
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
51.1%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (41/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 107.0% below Wall St target ($144.40)
- NEUTRAL: Bottoming setup forming (41/100) — watch for confirmation
- CAUTION: 5-day price weakness (-8.7%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$72.21 -
$75.61
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$68.35
Resistance Level
$77.76
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.43
Wall Street Target
$144.40
(+107.0%)
Revenue Growth (YoY)
-9.3%
Profit Margin
-287.8%
Share & Embed Analysis
Last updated: September 13, 2026 4:11 AM ET
Data refreshes hourly during market hours. Next update: 5:11 AM
Data refreshes hourly during market hours. Next update: 5:11 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NKTR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 50 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 49 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 41 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
